Literature DB >> 20598032

Sublingual versus vaginal misoprostol for the management of missed abortion.

Fateme Davari Tanha1, Mohadeseh Feizi, Mamak Shariat.   

Abstract

AIM: To evaluate the efficacy of two routes of misoprostol administration (sublingual and vaginal) for the treatment of missed abortion.
METHODS: Two hundred and twenty women with confirmed missed abortion who received 400 microg/6 h misoprostol either sublingually or vaginally, were included in this randomized control trial. All women were admitted to hospital for follow-up care for 2 days. If the pregnancy was not completely evacuated during this time, the patient underwent immediate surgical completion. Efficacy was defined as the percentage of women discharged from the study without the need for surgical intervention.
RESULTS: The effectiveness was high in the sublingual group and statistically different (sublingual 84.5%, vaginal 46.4% P = 0.000 RR = 0.54 95%CI = 0.442-0.681). The groups differed in terms of complications like bleeding (88.2% vs 65.5%), pain (85.5% vs 56.4%), diarrhea (69.1% vs 36.4%) and fever (23.6% vs 13.3%) in the sublingual group versus the vaginal group, but the mean time to expulsion was shorter (9.68 h SD = 5.51 95%CI = 8.61-10.57) in the sublingual group than the vaginal group (16.64 h SD = 14.01 95%CI = 13.8-19.48), P = 0.000. Women in the sublingual group were highly satisfied with the method.
CONCLUSION: Sublingual misoprostol for the medical management of missed abortion is more effective and more acceptable than the vaginal route. However, it showed more adverse effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20598032     DOI: 10.1111/j.1447-0756.2010.01229.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  9 in total

Review 1.  Medical methods for first trimester abortion.

Authors:  Jing Zhang; Kunyan Zhou; Dan Shan; Xiaoyan Luo
Journal:  Cochrane Database Syst Rev       Date:  2022-05-24

2.  Hysteroscopic management versus ultrasound-guided evacuation for women with first-trimester pregnancy loss, a randomised controlled trial.

Authors:  Hadeer Meshaal; Emad Salah; Eman Fawzy; Mazen Abdel-Rasheed; Ahmed Maged; Hany Saad
Journal:  BMC Womens Health       Date:  2022-05-25       Impact factor: 2.742

3.  Comparison Between Sublingual and Vaginal Administration of Misoprostol in Management of Missed Abortion.

Authors:  Hossam Hassan Aly Hassan El Sokkary
Journal:  J Obstet Gynaecol India       Date:  2015-08-25

Review 4.  Medical treatments for incomplete miscarriage (less than 24 weeks).

Authors:  James P Neilson; Gillian Ml Gyte; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 5.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

6.  Medical treatment for early fetal death (less than 24 weeks).

Authors:  Marike Lemmers; Marianne Ac Verschoor; Bobae Veronica Kim; Martha Hickey; Juan C Vazquez; Ben Willem J Mol; James P Neilson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

7.  Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis.

Authors:  Hang-Lin Wu; Sheeba Marwah; Pei Wang; Qiu-Meng Wang; Xiao-Wen Chen
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

8.  Methods for managing miscarriage: a network meta-analysis.

Authors:  Jay Ghosh; Argyro Papadopoulou; Adam J Devall; Hannah C Jeffery; Leanne E Beeson; Vivian Do; Malcolm J Price; Aurelio Tobias; Özge Tunçalp; Antonella Lavelanet; Ahmet Metin Gülmezoglu; Arri Coomarasamy; Ioannis D Gallos
Journal:  Cochrane Database Syst Rev       Date:  2021-06-01

9.  COMPARISON BETWEEN SUBLINGUAL AND VAGINAL ROUTE OF MISOPROSTOL IN MANAGEMENT OF FIRST TRIMESTER MISCARRIAGE MISSING.

Authors:  Zahra Dehbashi; Mahmood Moosazadeh; Mahdi Afshari
Journal:  Mater Sociomed       Date:  2016-07-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.